A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...
The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
Novo Nordisk said an agreement reached last year with privately held Lexington, Mass. company Valo Health that initially was valued at up to $2.7 billion is now been expanded to a $4.6 billion deal.
Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...
Research backs this up: Young men who consumed more protein while losing weight and on an intense exercise regiment gained ...
New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback